Meijer looks to turn pharmacists into go-to diabetes resources
GRAND RAPIDS, Mich. — Meijer has launched a chainwide effort to position its pharmacy staff as diabetes specialists.
The announcement was made by Effie Steele, the chain’s clinical services manager.
"A community pharmacist is an important first line of defense for diabetes and other diseases," Steele said. "So it was imperative that we placed more trained experts within our pharmacies for the benefit of our customers. Diabetes is a disease that has hit the Midwest hard, and there truly is an urgent need to take a much more active and aggressive role in combating it."
To aid the launch of the initiative, all 197 Meijer pharmacies will host a diabetes care event this Saturday from 11 a.m. until 3 p.m. The event will include free blood -glucose testing, as well as a free pharmacy patient education and sample kit. Meijer diabetes care pharmacists also will be on hand to assist with questions and explain Meijer’s free metformin prescription program.
Novo Nordisk donates $50,000 to Diabetes Hands Foundation
PRINCETON, N.J. — Novo Nordisk has donated $50,000 to an organization that raises awareness about diabetes and connects people living with it, the Danish drug maker said.
The company said the donation, to the Diabetes Hands Foundation, was meant to recognize the Drive the Switch program, which it said had motivated more than 10,000 people to pledge to talk to loved ones and their doctors about insulin options.
"Many people with diabetes don’t realize that they have options when it comes to their diabetes management," DHF president Manny Hernandez said. "This campaign has done a great job of encouraging patients and their caregivers to have that dialogue with their healthcare professional and determine the best treatment option for them."
FDA report: 35 new drugs approved in past year
SILVER SPRING, Md. — The Food and Drug Administration has approved 35 new drugs over the past 12 months, the agency said Thursday.
In a new report titled "FY 2011 Innovative Drug Approvals," the agency said many of the drugs were important advances for patents, including two new drugs for hepatitis C, one for late-stage prostate cancer, the first new drug for Hodgkin’s lymphoma in 30 years and the first new drug for lupus in 50 years. Others included one drug for melanoma and another for lung cancer that were approved with diagnostic tests — approvals that the FDA said were breakthroughs in personalized medicine. Ten of the new drugs are for rare, "orphan" disease states, such as hereditary angioedema.
"Thirty-five major drug approvals in one year represents a very strong performance, both by industry and by the FDA, and we continue to use every resource possible to get new treatments to patients," FDA commissioner Margaret Hamburg said. "We are committed to working with the industry to promote the science and innovation it takes to produce breakthrough treatments and to ensure that our nation is fully equipped to address the public health challenges of the 21st century."
The FDA said the report shows faster approval times in the United States compared with similar agencies in other countries: Of the 35 new drugs, 24 received approval in the United States before any other country. Part of the reason for this, FDA Center for Drug Evaluation and Research director Janet Woodcock said, was the Prescription Drug User Fee Act, passed by Congress in 1992.
"Before the PDUFA program, American patients waited for new drugs long after they were available elsewhere," Woodcock said. "As a result of the user fee program, new drugs are rapidly available to patients in the United States while maintaining our high standards for safety and efficacy."
Click here to read the FDA’s report.